ArticleFrontiers in pharmacology2026
From heart to brain: a Case Report of individualized antithrombotic management for left ventricular thrombus and stroke in a young patient with acute myocardial infarction.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Left ventricular thrombus (LVT) is a serious complication of acute myocardial infarction (AMI), conferring a high risk of systemic embolism. The management of LVT becomes exceedingly challenging when complicated by acute ischemic stroke and recent percutaneous coronary intervention (PCI), creating a therapeutic trilemma that lacks guideline-directed recommendations. Case summary: A 27-year-old male with hypertension and diabetes presented with acute anterior ST-segment elevation myocardial infarction. Due to unsuccessful initial revascularization at a local hospital, he underwent delayed PCI on day 10 post-infarction at our center. On the first post-PCI day, he developed acute ischemic stroke, and echocardiography confirmed a mobile left ventricular thrombus as the embolic source. Navigating competing risks of stent thrombosis, hemorrhagic transformation, and recurrent embolism, an individualized six-phase antithrombotic strategy was implemented. This dynamic approach included acute-phase de-escalation, sequential anticoagulation with rivaroxaban followed by warfarin guided by thrombus response, stepwise de-escalation after complete revascularization, and eventual transition to long-term dual-pathway inhibition. Complete LVT resolution was achieved within 6 months, and the patient's neurological deficits fully recovered. No recurrent LVT, ischemic events, or major bleeding occurred during 18 months of follow-up. Conclusion: This case highlights the complex management challenges of left ventricular thrombus and acute stroke following myocardial infarction, and underscores the value of individualized, phased antithrombotic strategies guided by dynamic risk assessment and serial imaging, rather than rigid adherence to single-disease guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.